Polydentate ligands for modern radiopharmaceuticals containing ⁶⁴Cu – review

1. Bé MM, Chisté V, Dulieu C et al. Table of Radionuclides (Vol. 1 – A = 1 to 150). France, Bureau International des Poinds et Mesures, 2004, 311 p

2. Qaim SM. Decay data and production yields of some non-standard positron emitters used in PET. Q J Nucl Med Mol Imaging 2008; 52:111-120

3. Mathias CJ, Green MA, Morrison WB et al. Evaluation of Cu-PTSM as a tracer of tumor perfusion: comparison with labeled microspheres in spontaneous canine neoplasms. Nucl Med Biol 1994;21:83-87

4. Shelton ME, Green MA, Mathias CJ et al. Kinetics of Copper-PTSM in Isolated Hearts: A Novel Tracer for Measuring Blood Flow with Positron Emission Tomography. J Nucl Med 1989;30:1843-1847

5. Mathias CJ, Welch MJ, Raichle ME et al. Evaluation of a Potential Generator-Produced PET Tracer for Cerebral Perfusion Imaging: Single-Pass Cerebral Extraction Measurements and Imaging with Radiolabeled Cu-PTSM. J Nucl Med 1990;31:351-359

6. Lewis JS, Sharp TL, Laforest R et al. Tumor Uptake of Copper-Diacetyl-Bis(N4-Methylthiosemicarbazone): Effect of Changes in Tissue Oxygenation. J Nucl Med 2001;42:655

7. Sun X, Wuest M, Kovacs Z et al. In vivo behavior of copper-64-labeled methanephosphonate tetraaza macrocyclic ligands. J Biol Inorg Chem 2003;8:217-225

8. Michelle TM, Donnelly PS. Peptide Targeted Copper-64 Radiopharmaceuticals. Curr Top Med Chem 2011;11:500-520

9. Pettit LD, Steel L, Kowalik T et al. Specific binding of tyrosine residue in copper(II) complexes of Tyr-Pro-Gly-Tyr and Tyr-Gly-Pro-Tyr. J Chem Soc Dalton Trans 1985;6:1201-1205

10.Meares CF. Chelating agents for the binding of metal ions to antibodies. Nucl Med Biol 1986;13:311-318

11.Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol 2004;386:237-261

12.Cole WC, DeNardo SJ, Meares CF et al. Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B 1986;13:363–368

13.Cole WC, DeNardo SJ, Meares CF et al. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med 1987;28:83-90

14.Franz J, Freeman GM, Barefield EK et al. Labeling of antibodies with 64Cu using a conjugate containing a macrocyclic amine chelating agent. Int J Rad Appl Instrum B 1987;14:479-484

15.Morphy JR, Parker D, Kataky R et al. Towards Tumour Targeting with Cu-Radiolabelled Macrocyc1e-Antibody Conjugates. JCS Chem Commun 1989;5:792-794

16.Ping LW, Meyer LA, Capretto DA et al. Receptor-binding, biodistribution, and metabolism studies of (64)Cu-DOTA-Cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radiopharm 2008;23:158–171

17.Cai W, Wu Y, Chen K et al. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 2005; 66:9673–9681

18.Wu Y, Zhang X, Xiong Z et al. MicroPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 2005;46:1707–1718

19.Bass LA, Wang M, Welch MJ et al. In vivo transchelation of copper-64 from TETA octreotide to superoxide dismutase in rat liver. Bioconjugate Chem 2000;11:527–532

20.Prasanphanich AF, Prasant KN, Tammy LR et al. Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 2007;104:12462-12467

21.Woodin KS, Heroux KJ, Boswell CA et al. Kinetic inertness and electrochemical behavior of copper(II) tetraazamacrocyclic complexes: possible implications for in vivo stability. Eur J Inorg Chem 2005;2005:4829-4833

22.Boswell CA, Sun X, Niu W et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004;47:1465-1474

23.Sun X, Wuest M, Weisman GR et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands.J Med Chem 2002;45:469-477

24.Jones-Wilson TM, Deal KA, Anderson CJ et al. The in vivo behavior of copper-64-labeled azamacrocyclic compounds. Nucl Med Biol 1998;25:523-530

25.Lewis EA, Boyle RW, Archibald SJ. Ultrastable complexes for in vivo use: a bifunctional chelator incorporating a cross-bridged macrocycle. Chemical Commun 2004;19:2212-2213

26.Sprague JE, Peng Y, Sun X et al. Preparation and biological evaluation of copper-64-labeled Tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004;10:8674-8682

27.Wadas TJ, Anderson CJ. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Prot 2006;1:3062-3068

28.Stigers DJ, Ferdani R, Weisman GR et al. A new phosphonate pendant-armed cross-bridged tetraamine chelator accelerates copper(II) binding for radiopharmaceutical applications. Dalton Trans 2011;39:1699-1701

29.Ferdani R, Stigers DJ, Fiamengo AL et al. Synthesis, Cu(II) complexation, 64Cu-labeling and biological evaluation of cross-bridged cyclam chelators with phosphonate pendant arms. Dalton Trans 2012;41:1938-1950

30.DiBartolo NM, Sargeson AM, Donlevy TM et al. Synthesis of a new cage ligand, SarAr, and its complexation with selected transition metal ions for potential use in radioimaging. J Chem Soc Dalton Trans 2001;15:2303-2309

31.Lears KA, Ferdani R, Liang K et al. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 2011; 52:470-477

32.Voss SD, Smith SV, DiBartolo N et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci USA 2007; 104:1-5

33.Smith SV. Molecular imaging with copper-64. J Inorg Biochem 2004;98:1874-1901

34.Park G, Dadachova E, Przyborowska A et al. Synthesis of novel 1,3,5-cis,cis-triaminocyclohexane ligand based Cu(II) complexes as potential radiopharmaceuticals and correlation of structure and serum stability. Polyhedron 2001;20:3155-3163

35.Ma D, Lu F, Overstreet T et al. Novel chelating agents for potential clinical applications of copper. Nucl Med Biol 2002;29:91-105

36.Brady ED, Chong H-S, Milenic DE et al. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. Nucl Med Biol 2004;31:795-802